4月15日，据CDE官网消息，三生国健药业（上海）股份有限公司、沈阳三生制药有限责任公司联合申请药品“SSGJ-707注射液”，获得临床试验默示许可，受理号CXSL2400087。
公示信息显示，药品“SSGJ-707注射液”适应症：晚期非小细胞肺癌。
三生国健药业（上海）股份有限公司药品申请临床试验默示许可获受理
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.